News >

Questions With BTK Inhibitors and Anti-CD20 Combos Require Further Study in CLL

Jessica Hergert
Published: Friday, Apr 10, 2020

Farrukh Awan, MD

Farrukh Awan, MD

BTK inhibitors, such as ibrutinib (Imbruvica) and acalabrutinib (Calquence), have dramatically changed the treatment landscape of chronic lymphocytic leukemia (CLL), said Farrukh Awan, MD. However, the utility of these agents in combination with CD20-directed monoclonal antibodies, such as obinutuzumab (Gazyva), has yet to be fully fleshed out.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication